Side-by-side · Research reference

ChonlutenvsIGF-DES

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-MechanisticHUMAN-REVIEWED8/38 cited

BAnimal-StrongHUMAN-REVIEWED8/60 cited

Chonluten

Khavinson Bioregulator · Bronchial Mucosa

BronchialTarget tissue

In vitroEvidence tierAvolio 2022

THP-1Model systemAvolio 2022

Oral · Sublingual · Per Protocol

IGF-DES

IGF-1 Analogue · Truncated N-Terminal

~10×Potency vs IGF-1

ReducedIGFBP binding

ResearchStatus

Injection (local or systemic) · Research protocols onlyBredehöft 2008

01Mechanism of Action

Parameter

Chonluten

IGF-DES

Primary target

Bronchial epithelial cells and respiratory mucosa tissue complexes

IGF-1 receptor (IGF1R)Shields 2007

Pathway

Bioregulatory peptide interaction → modulation of proliferative and inflammatory pathways in monocyte/macrophage populationsAvolio 2022

IGF1R activation → PI3K/Akt & MAPK signaling → protein synthesis, proliferation

Downstream effect

Regulation of proliferative activity and inflammatory mediator production in respiratory-associated immune cellsAvolio 2022

Enhanced muscle protein synthesis, myoblast differentiation, reduced apoptosis, cell proliferation

Feedback intact?

—

Unknown — no human endocrine feedback data

Origin

Khavinson bioregulator peptide complex derived from bronchial mucosa tissue extract methodology

Synthetic truncation of native IGF-1 — removal of N-terminal Gly-Pro-Glu tripeptideBredehöft 2008

Antibody development

—

02Dosage Protocols

Parameter

Chonluten

IGF-DES

Typical protocol dose

10–20 mg / day

Russian bioregulator tradition dosing; not standardized in Western literature.

—

Frequency

Once or twice daily

Variable — daily to multiple times daily in research

Route

Oral (capsule) or sublingual

Sublingual claimed for enhanced bioavailability; not validated.

Subcutaneous or intramuscular (local injection favored)

Local delivery maximizes tissue-specific uptake.

Evidence basis

In vitro mechanistic

Animal models + in vitro only

Duration

10–30 days per cycle

Traditional Khavinson protocol; cyclic administration common.

—

Clinical validation

None (PubMed indexed)

—

Research dose range

—

10–100 ng/mL (in vitro); μg doses (animal models)

Highly context-dependent; no standardized human protocol.

Human data

—

None — no clinical trials

Half-life

—

Shorter than IGF-1 due to reduced IGFBP binding

Rapid tissue uptake, limited systemic circulation.

03Metabolic / Fat Loss Evidence

Parameter

Chonluten

IGF-DES

Primary mechanism

—

Indirect via muscle hypertrophy → metabolic rate elevation

Direct lipolysis

—

Minimal evidence — IGF-1 axis primarily anabolic, not lipolytic

Prostate model

—

Inhibited BPH cell proliferation when combined with vitamin D3 analogueCrescioli 2002

Context-specific anti-proliferative effect, not fat loss.

04Side Effects & Safety

Parameter

Chonluten

IGF-DES

Documented adverse events

No published safety data in PubMed-indexed literature

—

Theoretical risks

Peptide hypersensitivity, GI intolerance (uncharacterized)

—

Drug interactions

Unknown — no pharmacokinetic studies available

—

Pregnancy / lactation

No data — avoid

—

Hypoglycemia risk

—

Theoretical — IGF-1 axis enhances glucose uptake

Mitogenic risk

—

Chronic IGF-1 receptor activation may promote cell proliferation, potential tumor growthCrescioli 2002

Injection site reaction

—

Expected — erythema, irritation, local swelling

Edema / Fluid retention

—

Possible via sodium retention (IGF-1 axis effect)

Human safety data

—

Absent — no human trials, all effects theoretical or extrapolated

Unknown long-term effects

—

No chronic dosing studies in humans; endocrine, metabolic consequences unknown

Absolute Contraindications

Chonluten

·Known hypersensitivity to peptide components

IGF-DES

·Active malignancy or history of cancer (mitogenic risk)
·Pregnancy / lactation (no safety data)
·Hypoglycemia disorders

Relative Contraindications

Chonluten

·Pregnancy and lactation (insufficient data)
·Active malignancy (theoretical bioregulator concern)

IGF-DES

·Diabetes mellitus (unpredictable glucose effects)
·Renal or hepatic impairment (clearance unknown)
·Edema-prone conditions (heart failure, nephrotic syndrome)

05Administration Protocol

Parameter

Chonluten

IGF-DES

1. Preparation

Typically supplied as capsules or sublingual tablets. No reconstitution required. Store in cool, dry place away from light.

Des(1-3)IGF-1 has no approved human protocol. All administration details are derived from animal or in vitro research and should not be construed as medical guidance.

2. Oral route

Swallow capsule with water, 20–30 minutes before meals or as directed. Traditional Khavinson protocol emphasizes empty stomach for absorption.

Sterile water or bacteriostatic water per research protocol. Gently swirl; do not shake. Store reconstituted peptide at 2–8 °C.

3. Sublingual route

Place tablet under tongue, allow dissolution for 1–2 minutes. Avoid swallowing immediately. Claimed to bypass first-pass metabolism.

Subcutaneous (abdomen, thigh) or intramuscular (deltoid, vastus lateralis). Local injection to target tissue (e.g., muscle group) may enhance regional uptake.

4. Timing

Morning dose preferred; may split into twice-daily if higher dose used. Consistency emphasized in bioregulator protocols.

Frequency and timing vary by research design. Post-exercise or fasted state may theoretically enhance muscle uptake.

5. Cycle protocol

10–30 day cycles common in Russian tradition. Rest period of 1–3 months between cycles often recommended, though no published evidence for this approach.

27–31G insulin syringe for subcutaneous; 25–27G for intramuscular.

6. Monitoring

—

Glucose monitoring essential (hypoglycemia risk). No established IGF-1 or safety labs for human use.

06Stack Synergy

Chonluten

— no documented stacks

IGF-DES

+ BPC-157

Moderate

View BPC-157 →

Des(1-3)IGF-1 promotes myoblast differentiation and protein synthesis, while BPC-157 enhances tissue repair, angiogenesis, and collagen synthesis. Both act on distinct pathways (IGF1R vs gastric pentadecapeptide mechanisms) to support muscle recovery and connective tissue integrity. Synergy is mechanistic but lacks direct co-administration studies.

Des(1-3)IGF-1: Research dose post-workout (local IM)
BPC-157: 250–500 mcg SQ, daily or twice daily
Frequency: Daily or per research protocol
Primary benefit: Accelerated muscle repair, enhanced hypertrophy, connective tissue support

+ TB-500

Moderate

View TB-500 →

TB-500 (Thymosin Beta-4 fragment) promotes cell migration, angiogenesis, and wound healing via actin regulation. Des(1-3)IGF-1 drives protein synthesis and myoblast proliferation. Combined, these peptides may synergistically enhance muscle recovery, repair, and hypertrophy through complementary anabolic and regenerative pathways. No direct human co-administration data.

Des(1-3)IGF-1: Research dose post-workout (local IM)
TB-500: 2–5 mg SQ, 2× weekly
Frequency: Per research cycle
Primary benefit: Muscle hypertrophy, injury recovery, vascular support